Eli Lilly and Company (LLY) Shares Bought by Shell Asset Management Co.
Shell Asset Management Co. raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 309,504 shares of the company’s stock after buying an additional 1,021 shares during the period. Shell Asset Management Co.’s holdings in Eli Lilly and were worth $25,472,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the company. Quantitative Systematic Strategies LLC purchased a new position in Eli Lilly and during the first quarter valued at approximately $1,890,000. Ledyard National Bank boosted its position in Eli Lilly and by 10.4% in the first quarter. Ledyard National Bank now owns 3,254 shares of the company’s stock valued at $274,000 after buying an additional 307 shares during the period. Rice Hall James & Associates LLC purchased a new position in Eli Lilly and during the first quarter valued at approximately $209,000. Bollard Group LLC boosted its position in Eli Lilly and by 2.7% in the first quarter. Bollard Group LLC now owns 313,974 shares of the company’s stock valued at $26,408,000 after buying an additional 8,153 shares during the period. Finally, Sabal Trust CO boosted its position in Eli Lilly and by 1.2% in the first quarter. Sabal Trust CO now owns 6,400 shares of the company’s stock valued at $538,000 after buying an additional 75 shares during the period. 75.77% of the stock is owned by institutional investors and hedge funds.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 80.49 on Thursday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The company’s 50-day moving average price is $81.83 and its 200-day moving average price is $81.93. The company has a market capitalization of $84.92 billion, a price-to-earnings ratio of 34.83 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.86 EPS. Equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.58%. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
Several research firms have commented on LLY. Berenberg Bank reaffirmed a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $88.00 price target on shares of Eli Lilly and in a report on Sunday, May 21st. TheStreet cut Eli Lilly and from a “b+” rating to a “c” rating in a report on Wednesday, May 31st. BMO Capital Markets reaffirmed an “underperform” rating and issued a $73.00 price target on shares of Eli Lilly and in a report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. cut Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target for the company. in a report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and an average price target of $87.92.
In other Eli Lilly and news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by corporate insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.